Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 6NIH 2INDIV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Other hematologic neoplasm 1Myeloid 1

Conditions

Melanoma 2Skin Neoplasms 1

Interventions

aldesleukin 69Cyclophosphamide 50fludarabine phosphate 36fludarabine 30Interleukin-2 27incomplete Freund's adjuvant 22Ipilimumab 20Biopsy 20Specimen Handling 19Magnetic Resonance Spectroscopy 19MART-1 Antigen 15CTLA-4 Antigen 15sargramostim 14Nivolumab 13Filgrastim 13montanide ISA 51 12Sorafenib 12Interferon-alpha 11pembrolizumab 10trametinib 9Temozolomide 9Bevacizumab 9dabrafenib 8temsirolimus 7Sirolimus 7Gene Expression Profiling 7tanespimycin 6Paclitaxel 6Dacarbazine 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Peptides × Dermatologic × Clear all
NCT00923195 2015-10-28

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
4 enrolled 11 charts
Dermatologic

Melanoma, Skin Neoplasms

NCT01989559 2015-01-26

Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡